Molecular Mechanisms of Infectious Pathogen Adaptation, Emergence, and Re-emergence

A special issue of Biomolecules (ISSN 2218-273X). This special issue belongs to the section "Molecular Medicine".

Deadline for manuscript submissions: 31 May 2025 | Viewed by 7052

Special Issue Editors


E-Mail Website
Guest Editor
Institute of Biostructures and Bioimaging, CNR, Via Mezzocannone 16, I-80134 Napoli, Italy
Interests: structural biology; biophysics; infectious diseases; vaccine
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Institute of Biostructures and Bioimaging, CNR, Via Mezzocannone 16, I-80134 Napoli, Italy
Interests: structural biology; molecular biology; biochemistry; infection disease
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Pathogen emergence is a complex phenomenon due to multiple factors, like genetic adaptations, selective pressure by the human host, and antibiotic or antiviral pressure. Among re-emerging respiratory pathogens, tuberculosis (TB) is one of the leading causes of death by infection, especially in immunocompromised patients (e.g., those with HIV). Rising rates of TB antibiotic resistance have been recorded around the world, making these bacteria immune to anti-TB drugs. TB can persist in many infected individuals in a latent state for many years and can be reactivated to cause disease. Children and adults with other disease like HIV are more prone to being affected. In most healthy people, the immune system can destroy the bacteria, whereas in some cases, TB infection begins without symptoms before becoming active (latent TB) and can persist for weeks, months, or years. New antibacterial strategies are needed to manage the global challenge of antimicrobial resistance in TB infection, to tackle both active TB and the threat of M. tuberculosis resuscitation. Also, the ESKAPE group of pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, A. baumannii, Pseudomonas aeruginosa, and Enterobacter spp.) are leading causes of nosocomial infections, with some of them declared by the World Health Organization (WHO) as critical, owing to their formidable adaptability and resistance to antimicrobial therapies. Adaptation mechanisms to drugs and to the host are also the ace in the hole of pandemic viruses, like SARS-CoV2, which exploit the host to enhance their viral infecting efficacy.

To address all these issues, comprehensive knowledge of important macromolecules regulating pathogen physiopathology is essential. In the last few decades, extensive studies have been performed aimed at the structural and functional characterization of the key molecular players involved virulence and adaptation to either drugs or to their hosts. This Special Issue offers an open access platform that aims to bring together a collection of research articles, reviews, and perspectives to address various aspects of pathogen emergence and re-emergence and the development of therapeutic tools against difficult pathogens.

Dr. Rita Berisio
Dr. Alessia Ruggiero
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomolecules is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • pathogen
  • structural biology
  • tuberculosis
  • function
  • molecular mechanism

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Related Special Issue

Published Papers (3 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Review

23 pages, 4569 KiB  
Article
Epimaps of the SARS-CoV-2 Receptor-Binding Domain Mutational Landscape: Insights into Protein Stability, Epitope Prediction, and Antibody Binding
by Eleni Pitsillou, Assam El-Osta, Andrew Hung and Tom C. Karagiannis
Biomolecules 2025, 15(2), 301; https://doi.org/10.3390/biom15020301 - 18 Feb 2025
Viewed by 712
Abstract
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants poses an ongoing threat to the efficacy of vaccines and therapeutic antibodies. Mutations predominantly affect the receptor-binding domain (RBD) of the spike protein, which mediates viral entry. The RBD is also a [...] Read more.
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants poses an ongoing threat to the efficacy of vaccines and therapeutic antibodies. Mutations predominantly affect the receptor-binding domain (RBD) of the spike protein, which mediates viral entry. The RBD is also a major target of monoclonal antibodies that were authorised for use during the pandemic. In this study, an in silico approach was used to investigate the mutational landscape of SARS-CoV-2 RBD variants, including currently circulating Omicron subvariants. A total of 40 single-point mutations were assessed for their potential effect on protein stability and dynamics. Destabilising effects were predicted for mutations such as L455S and F456L, while stabilising effects were predicted for mutations such as R346T. Conformational B-cell epitope predictions were subsequently performed for wild-type (WT) and variant RBDs. Mutations from SARS-CoV-2 variants were located within the predicted epitope residues and the epitope regions were found to correspond to the sites targeted by therapeutic antibodies. Furthermore, homology models of the RBD of SARS-CoV-2 variants were generated and were utilised for protein–antibody docking. The binding characteristics of 10 monoclonal antibodies against WT and 14 SARS-CoV-2 variants were evaluated. Through evaluating the binding affinities, interactions, and energy contributions of RBD residues, mutations that were contributing to viral evasion were identified. The findings from this study provide insight into the structural and molecular mechanisms underlying neutralising antibody evasion. Future antibody development could focus on broadly neutralising antibodies, engineering antibodies with enhanced binding affinity, and targeting spike protein regions beyond the RBD. Full article
Show Figures

Figure 1

Review

Jump to: Research

11 pages, 4772 KiB  
Review
HtpG—A Major Virulence Factor and a Promising Vaccine Antigen against Mycobacterium tuberculosis
by Rita Berisio, Giovanni Barra, Valeria Napolitano, Mario Privitera, Maria Romano, Flavia Squeglia and Alessia Ruggiero
Biomolecules 2024, 14(4), 471; https://doi.org/10.3390/biom14040471 - 11 Apr 2024
Cited by 1 | Viewed by 2102
Abstract
Tuberculosis (TB) is the leading global cause of death f rom an infectious bacterial agent. Therefore, limiting its epidemic spread is a pressing global health priority. The chaperone-like protein HtpG of M. tuberculosis (Mtb) is a large dimeric and multi-domain protein with a [...] Read more.
Tuberculosis (TB) is the leading global cause of death f rom an infectious bacterial agent. Therefore, limiting its epidemic spread is a pressing global health priority. The chaperone-like protein HtpG of M. tuberculosis (Mtb) is a large dimeric and multi-domain protein with a key role in Mtb pathogenesis and promising antigenic properties. This dual role, likely associated with the ability of Heat Shock proteins to act both intra- and extra-cellularly, makes HtpG highly exploitable both for drug and vaccine development. This review aims to gather the latest updates in HtpG structure and biological function, with HtpG operating in conjunction with a large number of chaperone molecules of Mtb. Altogether, these molecules help Mtb recovery after exposure to host-like stress by assisting the whole path of protein folding rescue, from the solubilisation of aggregated proteins to their refolding. Also, we highlight the role of structural biology in the development of safer and more effective subunit antigens. The larger availability of structural information on Mtb antigens and a better understanding of the host immune response to TB infection will aid the acceleration of TB vaccine development. Full article
Show Figures

Figure 1

18 pages, 1057 KiB  
Review
An Overview of SARS-CoV-2 Etiopathogenesis and Recent Developments in COVID-19 Vaccines
by Dona Susan Mathew, Tirtha Pandya, Het Pandya, Yuzen Vaghela and Selvakumar Subbian
Biomolecules 2023, 13(11), 1565; https://doi.org/10.3390/biom13111565 - 24 Oct 2023
Cited by 4 | Viewed by 3368
Abstract
The Coronavirus disease-2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has significantly impacted the health and socioeconomic status of humans worldwide. Pulmonary infection of SARS-CoV-2 results in exorbitant viral replication and associated onset of inflammatory cytokine storm and disease pathology [...] Read more.
The Coronavirus disease-2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has significantly impacted the health and socioeconomic status of humans worldwide. Pulmonary infection of SARS-CoV-2 results in exorbitant viral replication and associated onset of inflammatory cytokine storm and disease pathology in various internal organs. However, the etiopathogenesis of SARS-CoV-2 infection is not fully understood. Currently, there are no targeted therapies available to cure COVID-19, and most patients are treated empirically with anti-inflammatory and/or anti-viral drugs, based on the disease symptoms. Although several types of vaccines are currently implemented to control COVID-19 and prevent viral dissemination, the emergence of new variants of SARS-CoV-2 that can evade the vaccine-induced protective immunity poses challenges to current vaccination strategies and highlights the necessity to develop better and improved vaccines. In this review, we summarize the etiopathogenesis of SARS-CoV-2 and elaborately discuss various types of vaccines and vaccination strategies, focusing on those vaccines that are currently in use worldwide to combat COVID-19 or in various stages of clinical development to use in humans. Full article
Show Figures

Figure 1

Back to TopTop